TYK2 Inhibitors: A New Frontier in Psoriasis and Autoimmune Disease

Tyrosine kinase 2 (TYK2) is the newest member of the Janus kinase family to become a validated drug target. Selective TYK2 inhibitors represent a significant advance in the treatment of psoriasis and show promise in multiple autoimmune conditions, offering the efficacy of JAK inhibition with a potentially more favorable safety profile.

TYK2 Biology and Therapeutic Rationale

TYK2 mediates intracellular signaling for IL-12 and IL-23, which drive Th1 and Th17 differentiation respectively, and for type I interferons (IFN-alpha/beta), which mediate antiviral responses. The IL-12/IL-23/TYK2 axis is central to the pathogenesis of psoriasis, psoriatic arthritis, inflammatory bowel disease, and lupus.

Genetic evidence strongly validates TYK2 as a target: loss-of-function variants in TYK2 are associated with protection from psoriasis, Crohn's disease, rheumatoid arthritis, and lupus in human genetic studies—while conferring only modest susceptibility to certain infections.

Deucravacitinib: A Selective TYK2 Inhibitor

Deucravacitinib (Sotyktu, Bristol Myers Squibb) uses a novel allosteric mechanism—binding to the pseudokinase (JH2) regulatory domain of TYK2 rather than the active kinase domain (JH1). This approach provides exquisite selectivity for TYK2 over JAK1, JAK2, and JAK3, since the pseudokinase domains of the JAK family members differ more than their active kinase domains.

The pivotal POETYK PSO-1 and PSO-2 trials in moderate-to-severe plaque psoriasis demonstrated PASI 75 response rates of approximately 53-58% at week 16, significantly superior to apremilast. Long-term extension data show maintained efficacy and a favorable safety profile—importantly, no increased incidence of venous thromboembolism, major adverse cardiovascular events, or opportunistic infections compared to placebo.

TYK2 Inhibitors in the Pipeline

Multiple TYK2 inhibitors are in clinical development. Izokibep and other compounds are being evaluated in psoriasis, psoriatic arthritis, lupus, and inflammatory bowel disease. The allosteric mechanism used by deucravacitinib has been adapted by other developers, while some are developing active-site TYK2 inhibitors with different selectivity profiles.

Clinical Positioning of TYK2 Inhibitors

TYK2 inhibitors occupy a novel niche: they provide oral targeted therapy with a mechanism similar to biologics (targeting IL-12/IL-23 pathway) but as small molecules. This positions them between topical/systemic conventional therapies and injectable biologic therapies, potentially appealing to patients and physicians seeking oral options with biologic-like selectivity and safety.

For more on cutting-edge JAK and TYK2 inhibitor research, visit our blog.